Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions: Table 1

Snoek, Eric M van der; Hollander, Jan C. den; Ende, Marchina E. van der

doi:10.1136/sextrans-2014-051810

Cited by 22 publications

(17 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,13,[15][16][17][18][19] However, in most studies, patients with condylomas and low-and high-grade dysplasia at both intra-anal and perianal sites have been analyzed together, making it hard to draw firm conclusions on efficacy. 12,13,[15][16][17][18]20,21 Previously reported response rates to imiquimod for the treatment of any degree of anal dysplasia (AIN-1-3) vary within a wide range from 35 to 68%. 12,13,[16][17][18] In contrast, the current study shows a relatively lower CR rate (approximately 4%) which is likely related to the strict inclusion criteria limited to HSIL.…”

Section: Discussionmentioning

confidence: 99%

“…12,13,[15][16][17][18][19] Their results should be cautiously interpreted since the majority of them have analyzed heterogeneous cohorts of patients. 12,13,[15][16][17][18]20,21 Despite a large number of publications on imiquimod efficacy in the treatment of external genital and perianal warts, [22][23][24][25] safety and efficacy data for the treatment of intra-anal condylomas has rarely been evaluated. 14,20,26 Furthermore, data regarding the tolerability profile of topical imiquimod for treating anal HPV-associated pathology are also very limited.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

et al. 2019

View full text Add to dashboard Cite

Topical imiquimod is a potential treatment for intra-anal condyloma and squamous intraepithelial lesions caused by human papillomavirus (HPV). We aimed to assess the effectiveness and tolerability of imiquimod suppositories for the treatment of anal high-grade intraepithelial lesions (HSIL) and condylomas in HIV-infected patients. We conducted a retrospective analysis in a prospectively followed cohort. High-resolution anoscopy was used for diagnosis and assessment following treatment. Patients’ tolerability was assessed with a self-administered survey. Ninety-five patients (94.7% men) were analyzed. All were on combination antiretroviral therapy. Median CD4 T-cell count was 690 cells/µL, 89% had undetectable plasma viral load. Response to imiquimod was seen in 46.3% (complete: 12.5%, partial: 33.8%) in the intent-to-treat analysis, and in 55.2% (complete: 14.9%, partial: 40.3%) in the on-treatment analysis. Higher response rates were observed for anal condyloma compared with HSIL. A significantly poorer response rate was observed in smokers and in individuals with lower nadir CD4 T-cell counts. Imiquimod tolerability was “good” in 57.1% (n = 36), “acceptable” in 33.3% (n = 21), and “poor” in 9.5% (n = 6). Systemic side effects were reported in 20.7% (n = 13). There was no association between treatment effect and tolerability. In conclusion, imiquimod stands as a well-tolerated option for the treatment of HPV-associated intra-anal pathology in HIV-infected individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Это связано либо с высокой частотой рецидивирования (аногенитальные бородавки), склонностью к малигнизации (плоскоклеточный рак кожи) или быстро формирующейся резистентностью к противовирусным препаратам (ВПГ). В этих ситуациях имихимод может стать дополнительной альтернативой недостаточно эффективной или совсем неэффективной терапии [8,24,25], что особенно актуально при лечении атипичных форм генитального герпеса у ВИЧ-инфицированных больных, для которых характерны торпидное течение, высокий риск рецидивов и множественная лекарственная устойчивость [25].…”

Section: результатыunclassified

Influence of the Imiquimod on the Interferon Production and Treatment of the Experimental Herpes Simplex Virus Infection

Сергеевич¹,

Petlenko²

2017

Problems of Virology

View full text Add to dashboard Cite

Background. Imiquimod is an imidazole derivative acting as an immunomodulator on the level of innate and adaptive immune system. Our objective was to evaluate the antiviral activity of generically reproduced imiquimod administered subcutaneously in mice and intravaginally in guinea pigs against herpes simplex virus (HSV), as well as to study the dynamics of serum interferon (IFN) synthesis under different dosing regimens. Results. When administered subcutaneously at doses of 0.5, 1.0 and 10 mg/kg imiquimod increased IFN production in mice in a dose-dependent manner with maximum serum IFN concentrations occurring 4 hours after dosing. Imiquimod protected mice from intraperitoneal HSV infection at doses of 3.2 and 32 LD50.The utmost protection (100% survival) was observed when imiquimod was administered at a dose of 100 mg/kg daily for 5 days before infection. Topical application of imiquimod 5% cream exhibited significantly more rapid and complete virus elimination in guinea pigs intravaginally infected with HSV type 2 compared to control group. Conclusion. Imiquimod produced as a generic possesses the same immunomodulatory and antiviral properties as the originally synthesized substance.

show abstract

“…Imiquimod is a drug with anticarcinogenic and antiviral activity, and it is recommended for treatment of genital/perianal condylomas. It is not suggested for the treatment of anal HSIL; nevertheless, the results of two research studies about imiquimod in premalignant anal lesions in HIV-positive patients have been published with a cure rate of 45 to 61% [1,2]. The aim of this prospective study was to analyze the efficacy of 3 consecutive days a week for 4 months of self-administered treatment with imiquimod 5% cream for anal HSIL, and to assess safety, and antiviral activity against HPV, in seropositive patients.…”

mentioning

confidence: 99%

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

2016

Journal of the International AIDS Society

View full text Add to dashboard Cite

Scientific advances over the 35 years since AIDS was first recognized as a new disease, have put us on a clear path towards ending the HIV/AIDS pandemic. Scaling-up access to antiretroviral therapy (ART) and HIV prevention strategies, such as pre-exposure prophylaxis, could dramatically decrease HIV-related deaths and the rate of new HIV infections. Current and future scientific advances, notably in HIV vaccine and cure research, will accelerate this process. Two major directions in HIV vaccine development will be discussed: building on the results from RV 144, the clinical trial in Thailand that resulted in the first modest signal of efficacy for a HIV vaccine; and structure-based immunogen design to elicit broadly neutralizing antibodies. Cure research has accelerated greatly over the past few years in two areas. The first is the prospect of eradicating the HIV reservoir altogether (i.e. a classic cure), which might involve novel latency-reversing and immunotoxic regimens and gene editing techniques to create a host cellular environment that does not allow HIV replication. The second approach involves controlling viral rebound following discontinuation of ART to achieve sustained virological remission employing strategies, such as passive transfer of broadly neutralizing antibodies and therapeutic vaccination. In 2016, the arsenal of scientifically proven interventions available, as well as the hope of others to come, offer unprecedented opportunities to make major gains in the fight against HIV/AIDS. With a major global commitment to implement these scientific advances, the end of the HIV/AIDS pandemic is now achievable.

show abstract

Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions: Table 1

Cited by 22 publications

References 10 publications

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

Influence of the Imiquimod on the Interferon Production and Treatment of the Experimental Herpes Simplex Virus Infection

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Contact Info

Product

Resources

About